Literature DB >> 29801033

Hypopigmented Skin Lesions After Immunotherapy.

Ecaterina Ileana Dumbrava1, Doina Ivan2, Vivek Subbiah1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29801033      PMCID： PMC6529200          DOI： 10.1001/jamaoncol.2018.0186

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  10 in total

1.  Pseudoprogression and Immune-Related Response in Solid Tumors.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

2.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

Review 3.  Vitiligo.

Authors:  Khaled Ezzedine; Viktoria Eleftheriadou; Maxine Whitton; Nanja van Geel
Journal:  Lancet       Date:  2015-01-15       Impact factor: 79.321

Review 4.  Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

Authors:  Hansje-Eva Teulings; Jacqueline Limpens; Sophia N Jansen; Aeilko H Zwinderman; Johannes B Reitsma; Phyllis I Spuls; Rosalie M Luiten
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

5.  Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.

Authors:  T Okamoto; R F Irie; S Fujii; S K Huang; A J Nizze; D L Morton; D S Hoon
Journal:  J Invest Dermatol       Date:  1998-12       Impact factor: 8.551

Review 6.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Authors:  J M Michot; C Bigenwald; S Champiat; M Collins; F Carbonnel; S Postel-Vinay; A Berdelou; A Varga; R Bahleda; A Hollebecque; C Massard; A Fuerea; V Ribrag; A Gazzah; J P Armand; N Amellal; E Angevin; N Noel; C Boutros; C Mateus; C Robert; J C Soria; A Marabelle; O Lambotte
Journal:  Eur J Cancer       Date:  2016-01-05       Impact factor: 9.162

7.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

Authors:  Camille Hua; Lise Boussemart; Christine Mateus; Emilie Routier; Céline Boutros; Hugo Cazenave; Roxane Viollet; Marina Thomas; Séverine Roy; Naima Benannoune; Gorana Tomasic; Jean-Charles Soria; Stéphane Champiat; Matthieu Texier; Emilie Lanoy; Caroline Robert
Journal:  JAMA Dermatol       Date:  2016-01       Impact factor: 10.282

8.  Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.

Authors:  J Cui; J C Bystryn
Journal:  Arch Dermatol       Date:  1995-03

9.  Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.

Authors:  Yasuhiro Nakamura; Ryota Tanaka; Yuri Asami; Yukiko Teramoto; Taichi Imamura; Sayuri Sato; Hiroshi Maruyama; Yasuhiro Fujisawa; Taisuke Matsuya; Manabu Fujimoto; Akifumi Yamamoto
Journal:  J Dermatol       Date:  2016-08-11       Impact factor: 4.005

10.  Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding.

Authors:  Emily S Yin; Mariam B Totonchy; Jonathan S Leventhal
Journal:  JAAD Case Rep       Date:  2017-03-02
  10 in total
  5 in total

Review 1.  Immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-23       Impact factor: 11.527

2.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Authors:  Gregory S Phillips; Jennifer Wu; Matthew D Hellmann; Michael A Postow; Naiyer A Rizvi; Azael Freites-Martinez; Donald Chan; Stephen Dusza; Robert J Motzer; Jonathan E Rosenberg; Margaret K Callahan; Paul B Chapman; Larisa Geskin; Adriana T Lopez; Vanessa A Reed; Gabriella Fabbrocini; Maria Carmela Annunziata; Oluwaseun Kukoyi; Aliyah Pabani; Chih-Hsun Yang; Wen-Hung Chung; Alina Markova; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2019-06-19       Impact factor: 50.717

3.  Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review.

Authors:  Rafael A Schmerling; Antonio C Buzaid; Carolina K Haddad; Fabio Ab Schutz; Fabio R Kater; Juliana Pimenta; Fernando Maluf; William N William; Camila Lopes; Dafne R Bromberg; Ana C Oliveira; Ricardo Golmia; Morton Scheinberg
Journal:  Future Sci OA       Date:  2020-11-23

4.  Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.

Authors:  Cristian Lolli; Matelda Medri; Michela Ricci; Giuseppe Schepisi; Alessia Filograna; Ugo De Giorgi; Ignazio Stanganelli
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

5.  Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report.

Authors:  Sook Jung Yun; In-Jae Oh; Cheol Kyu Park; Young-Chul Kim; Hyeon Bin Kim; Hee-Kyung Kim; A Ram Hong; In-Young Kim; Sung-Ja Ahn; Kook-Joo Na; Yoo-Duk Choi
Journal:  Transl Lung Cancer Res       Date:  2020-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.